On November 19, 2021, the Drug Enforcement Administration (“DEA”) issued a Notice of Proposed Rulemaking (“NPRM”) “to allow the transfer of electronic prescriptions for schedule II-V controlled substances between registered retail pharmacies for initial filling on a one-time basis.”
Continue Reading New DEA Regulation Addresses Transfers of Prescriptions
On November 17, 2021, the Drug Enforcement Administration (DEA) issued an Advanced Notice of Proposed Rulemaking (the “Notice”) seeking the public’s help with understanding the “practice, industry, and state regulations of telepharmacy.”
As DEA acknowledges in the Notice, telepharmacy is
Continue Reading DEA Seeks Your Help with the Practice of Telepharmacy
When was the last time you went to an in-person conference? Well, it’s time. The American Society of Pharmacy Law is meeting in person (and virtually) this year in Summerlin, Nevada for its 32nd Annual Pharmacy Law Seminar. The team
Continue Reading Annual ASPL Pharmacy Law Seminar is Back and In Person
The 2021 Healthcare Distribution Alliance Distribution Management Conference and Expo is still on! Yes, it’s virtual, and if you are involved in pharmaceutical distribution, you will want to register for one of the industry’s “must-attend” healthcare supply chain management events.
Continue Reading In Pharmaceutical Distribution? Join Me Virtually at the Distribution Management Conference
The COVID pandemic notwithstanding, the Drug Enforcement Administration (DEA), Department of Justice and other federal and state agencies continue to actively pursue and prosecute pharmacies, pharmacists, doctors and others in the industry for violations of the Controlled Substance Act, False
Continue Reading Active Prosecution Continues for Controlled Substance Violations
The Washington Post reports that the Biden Administration is preparing to pull back recent Health and Human Services (HHS) guidance designed to expand access to prescribing buprenorphine for opioid use disorders (OUD).
On January 14, 2021, HHS published Practice Guidelines
Continue Reading Not So Fast: Biden Expected to Halt Expansion of Buprenorphine Prescribing
As I was reviewing the public comments regarding the Drug Enforcement Administration’s (DEA’s) Notice of Proposed Rulemaking (NPRM) providing a much-needed update to the agency’s suspicious order regulations, I noticed a similar issue raised by multiple commenters. Apart from the
Continue Reading Confusion Persists with the 5% Rule
More than four years ago, the Comprehensive Addiction and Recovery Act of 2016 (“CARA”) was signed into law. CARA, among other things, includes provisions allowing for the partial filling of prescriptions for Schedule II controlled substances. On December 4, 2020,
Continue Reading DEA Proposes Regulations for Partial Fills of C-IIs
Update: DEA has reopened the comment period for the proposed rulemaking from February 25, 2021, until March 29, 2021.
The Drug Enforcement Administration (DEA) published its long-awaited Notice of Proposed Rulemaking (NPRM) regarding suspicious orders of controlled substances. This
Continue Reading DEA Creates Two-Option Framework for Reporting Suspicious Orders
Pharmacies and pharmacists have always been on the front lines in terms of medication safety and the pandemic has produced a new layer of challenges for the industry. I know we are all tired of Zoom meetings (and cheesy headlines),
Continue Reading ASPL Virtual Conference: Your Rx for Developments in Pharmacy Law
